{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:06:33Z","timestamp":1750694793103,"version":"3.41.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Fixed-dose combination of dolutegravir (DTG) with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) likely improves adherence and has a favorable resistance profile. We evaluated predicted efficacy of TLD (TDF-3TC-DTG) in children and adolescents failing abacavir (ABC), zidovudine (AZT), or TDF containing regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Drug resistance mutations were analyzed in a retrospective dataset of individuals &lt;19 years of age, failing ABC (n = 293) AZT (n = 288) or TDF (n = 69) based treatment. <jats:italic toggle=\"yes\">Pol<\/jats:italic> sequences were submitted to Stanford HIVdb v8.9. Genotypic susceptibility scores were calculated for various DTG-containing regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Genotypes were assessed for 650 individuals with a median age of 14 years (IQR 10-17 years). More individuals failed a protease inhibitor (PI)-based (78.3%) than a non-nucleoside reverse transcriptase inhibitors (NNRTI)-based (21.7%) regimen. Most individuals in the AZT group (n = 288; 94.4%) failed a PI-based regimen, compared with 71.0% and 64.2% in the TDF (n = 69) and ABC group (n = 293). Genotypic sensitivity scores &lt;2 to TLD were observed in 8.5% and 9.4% of ABC- and AZT-exposed individuals, compared with 23.2% in the TDF group. The M184V mutation was most often detected in the ABC group (70.6%) versus 60.0% and 52.4% in TDF and AZT groups. The presence of K65R was rare (n = 13, 2.0%) and reduced TLD susceptibility was commonly caused by accumulation of nucleoside reverse transcriptase inhibitor (NRTI) mutations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cross-resistance to TDF was limited, further reducing concerns about use of transition to TLD in children and adolescents. The NADIA trial has subsequently shown that patients failing a TDF\/3TC\/EFV regimen can safely be transitioned to a TLD regimen but we do not have data for patients failing an ABC\/3TC\/NNRTI or PI regimens. Frequent virological monitoring is recommended after switch to DTG, especially in children continuing ABC in the backbone. Clinical studies correlating predicted resistance with clinical outcomes, especially in settings without access to genotyping, are required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003647","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:19:21Z","timestamp":1658967561000},"page":"827-834","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-7685","authenticated-orcid":false,"given":"Kim","family":"Steegen","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Haematology National Health Laboratory Services, Johannesburg, South Africa"},{"name":"Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-6480","authenticated-orcid":false,"given":"Leon","family":"Levin","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Right to Care, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-1228","authenticated-orcid":false,"given":"Denise","family":"Evans","sequence":"additional","affiliation":[{"name":"Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-7512","authenticated-orcid":false,"given":"Karl-G\u00fcnter","family":"Technau","sequence":"additional","affiliation":[{"name":"Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-4857","authenticated-orcid":false,"given":"Lucia","family":"Hans","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Haematology National Health Laboratory Services, Johannesburg, South Africa"},{"name":"Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies.","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"e28184","DOI":"10.1371\/journal.pone.0028184","article-title":"Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/bioinformatics\/btl158","article-title":"Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences.","volume":"22","author":"Li","year":"2006","journal-title":"Bioinformatics"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance.","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R12-20250614","first-page":"4161738","article-title":"Insights into adherence among a cohort of adolescents Aged 12-20 years in South Africa: reported barriers to antiretroviral treatment.","volume":"2016","author":"Maskew","year":"2016","journal-title":"AIDS Res Treat"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01109-08","article-title":"Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.","volume":"53","author":"Ntemgwa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/jac\/dkx091","article-title":"An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.","volume":"72","author":"Smit","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"e20208","DOI":"10.1371\/journal.pone.0020208","article-title":"A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.","volume":"6","author":"Coutsinos","year":"2011","journal-title":"PLoS One"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","article-title":"First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3 trial.","volume":"11","author":"Babiker","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00126334-200207010-00003","article-title":"Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.","volume":"30","author":"Walsh","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e2783","DOI":"10.1371\/journal.pone.0002783","article-title":"Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.","volume":"3","author":"Parienti","year":"2008","journal-title":"PLoS One"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1086\/383572","article-title":"Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.","volume":"38","author":"Parienti","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QAI.0b013e318227fc34","article-title":"Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.","volume":"58","author":"Sigaloff","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-20250614","first-page":"967073","article-title":"The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis.","volume":"2014","author":"van Galen","year":"2014","journal-title":"AIDS Res Treat"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa.","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.","volume":"35","author":"Keene","year":"2021","journal-title":"AIDS"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:07:00Z","timestamp":1749946020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003647","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}